Taken together, these findings opened up the potential that DDR inhibition combined with radiation therapy could be a novel therapeutic approach for IDH1 R132H glioma patients harboring ATRX and TP53 inactivating mutations. The gene discussed is ATRX; the disease is central nervous system cancer.